Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.
暂无分享,去创建一个
N. Socci | A. Viale | A. Ferrando | M. Gönen | O. Abdel-Wahab | A. Heguy | A. Melnick | M. Figueroa | R. Levine | A. Cherry | I. Dolgalev | K. Huberman | M. V. D. van den Brink | M. Tallman | G. Vance | P. Van Vlierberghe | H. Lazarus | E. Paietta | J. Racevskis | J. Rowe | Zhuoxin Sun | M. Litzow | R. Ketterling | H. Fernandez | Jay P. Patel | Sabrena Thomas | O. Aminova | Janice Cheng | R. Higgins | R. Gallagher | S. Luger | Olga S. Aminova | S. Thomas | Igor Dolgalev | R. Levine
[1] D. Rakheja,et al. IDH mutations in acute myeloid leukemia. , 2012, Human pathology.
[2] M. Caligiuri,et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. , 2011, Blood.
[3] M. Caligiuri,et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Licht,et al. DNMT3A mutations in acute myeloid leukemia , 2011, Nature Genetics.
[5] Yong-mei Zhu,et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia , 2011, Nature Genetics.
[6] Torsten Haferlach,et al. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] A. Ferrando,et al. PHF6 mutations in adult acute myeloid leukemia , 2011, Leukemia.
[8] J. Licht,et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.
[9] M. Caligiuri,et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Omar Abdel-Wahab,et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.
[11] J. Soulier,et al. Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.
[12] H. Döhner,et al. High-dose daunorubicin in older patients with acute myeloid leukemia. , 2009, The New England journal of medicine.
[13] Ken Chen,et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.
[14] D. Gilliland,et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. , 2009, Blood.
[15] M. Patnaik,et al. Anthracycline dose intensification in acute myeloid leukemia. , 2009, The New England journal of medicine.
[16] Axel Benner,et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.
[17] R. Tibshirani,et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. , 2004, The New England journal of medicine.
[18] R. Verhaak,et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. , 2004, The New England journal of medicine.
[19] S. Fröhling,et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Axel Benner,et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. , 2002, Blood.
[21] C. Bloomfield,et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.
[22] M. Slovak,et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. , 2000, Blood.
[23] M. Caligiuri,et al. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. , 1998, Cancer research.
[24] J. Booth,et al. Resampling-Based Multiple Testing. , 1994 .